
Xiaobao Yang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/127684/publications.pdf Version: 2024-02-01



XIAOBAO YANG

#	Article	IF	CITATIONS
1	Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). European Journal of Medicinal Chemistry, 2018, 151, 304-314.	2.6	165
2	Discovery of a first-in-class EZH2 selective degrader. Nature Chemical Biology, 2020, 16, 214-222.	3.9	148
3	The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs. ACS Chemical Neuroscience, 2015, 6, 476-484.	1.7	128
4	Distinct cortical and striatal actions of a β-arrestin–biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8178-E8186.	3.3	117
5	Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase. Journal of Medicinal Chemistry, 2019, 62, 9281-9298.	2.9	79
6	Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems. European Journal of Medicinal Chemistry, 2021, 218, 113328.	2.6	55
7	Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. European Journal of Medicinal Chemistry, 2020, 193, 112190.	2.6	50
8	Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction. Organic Letters, 2019, 21, 3838-3841.	2.4	48
9	Structure–Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 7617-7633.	2.9	46
10	ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation. Nature Communications, 2022, 13, 703.	5.8	31
11	Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nature Cancer, 2021, 2, 429-443.	5.7	29
12	Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3). Journal of Medicinal Chemistry, 2018, 61, 1204-1217.	2.9	27
13	Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib. European Journal of Medicinal Chemistry, 2021, 217, 113335.	2.6	26
14	Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. Journal of Medicinal Chemistry, 2021, 64, 9152-9165.	2.9	23
15	Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2021, 223, 113645.	2.6	23
16	Construction of an IMiD-based azide library as a kit for PROTAC research. Organic and Biomolecular Chemistry, 2021, 19, 166-170.	1.5	21
17	Development of an MDM2 Degrader for Treatment of Acute Leukemias. Blood, 2021, 138, 1866-1866.	0.6	3
18	Abstract 41: Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state		0

of CDK6., 2021,,.